Advertisement
UK markets close in 3 hours 9 minutes
  • FTSE 100

    8,228.55
    +23.44 (+0.29%)
     
  • FTSE 250

    20,442.90
    +61.85 (+0.30%)
     
  • AIM

    773.74
    -3.76 (-0.48%)
     
  • GBP/EUR

    1.1832
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2688
    -0.0034 (-0.26%)
     
  • Bitcoin GBP

    52,048.28
    +750.05 (+1.46%)
     
  • CMC Crypto 200

    1,373.43
    -9.23 (-0.67%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CRUDE OIL

    81.59
    +0.02 (+0.02%)
     
  • GOLD FUTURES

    2,352.60
    +5.70 (+0.24%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     
  • DAX

    18,155.05
    +87.14 (+0.48%)
     
  • CAC 40

    7,631.99
    +61.79 (+0.82%)
     

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics, Inc
Black Diamond Therapeutics, Inc

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.

Presentation details are as follows:

  • 7:30-7:55am ET on Wednesday, June 5

A live webcast of the event can be accessed by visiting the investors relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

ADVERTISEMENT

About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com

For Media:
media@bdtx.com